Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-01-22T19:06:39.576Z Has data issue: false hasContentIssue false
  • English
  • Français

A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

The Canadian MS Research Group
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue 3 , August 1987 , pp. 273 - 278
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Freal, JE, Kraft, GH, Coryell, JK. Symptomatic fatigue in multiple sclerosis. Phys Med Rehabil 1984; 65: 135–138.Google ScholarPubMed
2.Murray, TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985; 12: 251–254.CrossRefGoogle ScholarPubMed
3.Schapira, M. Treating multiple sclerosis with amantadine hydro-chloride. J Royal Coll Gen Prac 1974; 24: 411–412.Google Scholar
5.Ellison, GW, Mickey, MR, Myers, LW, et al. A pilot study of amantadine treatment of multiple sclerosis. In: Progress in Multi-ple Sclerosis Research. Bauer, HF, Doser, S, Ritter, G, eds. Berlin: Springer-Verlag, 1980; 407.CrossRefGoogle Scholar
5.Schumacher, GA, Beebe, G, Kibler, RF, et al. Problems of experi-mental trials of therapy in MS: Report of the panel on evaluation of experimental trials in MS. Ann NY Acad Sci 1986; 122: 552–568.CrossRefGoogle Scholar
6.Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 1444–1452.CrossRefGoogle ScholarPubMed
7.Beck, AT, Ward, CH, Mendelson, M, et al. An inventory for measur-ing depression. Arch Gen Psych 1961; 4: 53–63.CrossRefGoogle Scholar
8.Lips, HM, Ng, M. Use of the Beck Depression Inventory with three non-clinical populations. Can J Behav Sci 1985; 18: 62–74.CrossRefGoogle Scholar
9.Vale, S, Espejel, MA, Dominguez, JC. Amantadine in depression. Lancet 1971; 2: 437.CrossRefGoogle ScholarPubMed
10.Rizzo, M, Biandrate, P, Tognomi, G, et al. Amantadine in depression: relationship between behavioral effects and plasma levels. Europ J Clin Pharmacol 1973; 5: 226–228.CrossRefGoogle Scholar
11.McFarlin, DE. Treatment of multiple sclerosis. New Eng J Med 1983; 308: 215–217.CrossRefGoogle ScholarPubMed
12.Noseworthy, JH, Seland, TP, Ebers, GC. Therapeutic trials in multi-ple sclerosis. Can J Neurol Sci 1984; 11: 355–362.CrossRefGoogle Scholar
13.Scott, PJ, Huskisson, EC. Measurement of functional capacity with visual analogue scales. Rheumatol Rehab 1977; 16: 257–259.CrossRefGoogle ScholarPubMed
14.Plaut, GS. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J Royal Soc Med 1987; 80: 91–93.CrossRefGoogle ScholarPubMed
15.Scatton, B, Cheramy, A, Besson, MJ, et al. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 1970; 13: 131–133.CrossRefGoogle ScholarPubMed
16.Ersmark, B, Lidvall, H. Trial with amantadine in narcolepsy. Psychopharmacologia 1973; 28: 308.CrossRefGoogle ScholarPubMed
17.Sajadi, C, Pitts, W, Snyder, S, et al. Amantadine in narcolepsy. Clin Pharmacol Ther 1981; 29: 279.Google Scholar